Asia PacificENPublic regulatory overview
Taiwan
Country Overview Population: Approximately 23.4 million (2024); rapidly aging (aging rate approximately 19%) Healthcare system: National Health Insurance (NHI — 全民健保) covers approx...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.
Reference approval strategy
FDA / CE / MDSAP / NMPA benefits for this market
These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.
US FDA
510(k) / De Novo / PMAModerate benefitFDA evidence is useful technical and clinical support, but the local authority still performs an independent review.
Likely benefit
- Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
- May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
- Does not remove local holder, language, labeling, fee, import, or post-market obligations.
EU CE
MDR / IVDRModerate benefitCE evidence provides a strong technical-file template but does not replace the local review.
Likely benefit
- Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
- Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
- Does not replace local registration or local representative responsibilities outside the CE-recognized route.
MDSAP
Single QMS auditIndirect QMS signalMDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.
Likely benefit
- Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
- Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
- Does not authorize product sale and does not replace safety, performance, or clinical evidence.
China NMPA
China registration / filingDossier reuse onlyThe NMPA certificate itself has limited effect, but ISO/IEC-aligned test reports, clinical evidence, risk files, and PMS data can be reused after gap assessment.
Likely benefit
- Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
- Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
- Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
AI Citation Summary
- Country: Taiwan
- Product line: Medical devices
- Regulator / source: Regulatory maturity: High. TFDA (Taiwan Food and Drug Administration) operates a well-developed regulatory framework that is closely aligned with the US FDA system (classification standards largely correspond to FDA). Review timelines are relatively predictable. TFDA has been actively tracking EU MDR/IVDR developments in recent years.
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Regulatory maturity: High. TFDA (Taiwan Food and Drug Administration) operates a well-developed regulatory framework that is closely aligned with the US FDA system (classification standards largely correspond to FDA). Review timelines are relatively predictable. TFDA has been actively tracking EU MDR/IVDR developments in recent years.
- Key fees: Market characteristics: Market size approximately NTD 90 billion (approximately USD 2.8 billion) in 2023. A relatively strong domestic medical device industry exists (particularly IVD, dental materials, and diagnostic imaging equipment). Import dependence is approximately 55%. The US, Germany, and Japan are the primary import sources. Price competition is significant as NHI payment standards compress margins.
- Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Country Overview
- Population: Approximately 23.4 million (2024); rapidly aging (aging rate approximately 19%)
- Healthcare system: National Health Insurance (NHI — 全民健保) covers approximately 99% of the population — one of the most comprehensive universal health coverage systems globally. Public hospitals (National Taiwan University Hospital, Cheng Kung University Hospital, Chang Gung Memorial Hospital, and other major medical centers) dominate the landscape, supplemented by private hospitals. Medical technology standards are high, with exceptional per-capita hospital efficiency.
- Market characteristics: Market size approximately NTD 90 billion (approximately USD 2.8 billion) in 2023. A relatively strong domestic medical device industry exists (particularly IVD, dental materials, and diagnostic imaging equipment). Import dependence is approximately 55%. The US, Germany, and Japan are the primary import sources. Price competition is significant as NHI payment standards compress margins.
- Regulatory maturity: High. TFDA (Taiwan Food and Drug Administration) operates a well-developed regulatory framework that is closely aligned with the US FDA system (classification standards largely correspond to FDA). Review timelines are relatively predictable. TFDA has been actively tracking EU MDR/IVDR developments in recent years.
Regulatory Authority
- Primary authority: TFDA (Taiwan Food and Drug Administration — 食品藥物管理署), under the Ministry of Health and Welfare (MOHW — 衛生福利部)
- Official portal: https://www.fda.gov.tw; Medical Device Registration System: https://mdsystem.fda.gov.tw
- Key regulations:
- Medical Device Act (effective May 1, 2021; supersedes the medical device provisions of the Pharmaceutical Affairs Act)
- Review Guidelines for Medical Device Registration (TFDA announcement)
- Priority Registration Procedure for Medical Devices (innovative device fast-track pathway)
- Medical Device Classification and Grading Management Regulations
- Good Manufacturing Practice for Medical Devices (Quality System Documentation — QSD requirements)
Device Classification System
| Local Class | Risk Level | Approximate EU/FDA Equivalent | Notes |
|---|---|---|---|
| Class I (第一等級) | Low risk | EU Class I / FDA Class I | Listing system (simplified application); basic technical requirements; some exempt from full review |
| Class II (第二等級) | Moderate risk | EU Class IIa/IIb / FDA Class II (510(k)) | Registration review required; must pass TFDA technical review; analogous to 510(k) logic |
| Class III (第三等級) | High risk | EU Class III / FDA Class III (PMA) | Registration review required; most stringent technical review; clinical data required; analogous to PMA logic |
Note: Taiwan's classification system is highly aligned with FDA, with product codes closely corresponding to FDA's Product Code/Device Classification Database. IVD products (體外診斷醫療器材, IVMD) follow separate classification rules but use the same three-tier class structure.
Registration Pathways
During the limited-time free period, sign in or register to view the complete medical device country report.